CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Neurocrine Biosciences, Inc. - NBIX CFD

134.84
0.04%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 1.26
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-4.44)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.22)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 134.78
Open 134.7
1-Year Change 10.99%
Day's Range 134.7 - 136.82
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 134.84 2.26 1.70% 132.58 136.82 132.58
Dec 19, 2024 134.78 -0.04 -0.03% 134.82 136.25 132.55
Dec 18, 2024 134.92 -1.63 -1.19% 136.55 139.85 134.19
Dec 17, 2024 136.58 5.06 3.85% 131.52 137.08 131.43
Dec 16, 2024 132.75 6.08 4.80% 126.67 134.59 126.17
Dec 13, 2024 126.37 0.66 0.53% 125.71 126.98 125.10
Dec 12, 2024 126.31 -1.33 -1.04% 127.64 128.23 126.22
Dec 11, 2024 127.80 -0.90 -0.70% 128.70 129.60 126.93
Dec 10, 2024 128.80 0.25 0.19% 128.55 130.34 126.85
Dec 9, 2024 129.08 2.15 1.69% 126.93 129.37 126.93
Dec 6, 2024 127.73 1.49 1.18% 126.24 128.76 125.74
Dec 5, 2024 126.32 0.75 0.60% 125.57 127.47 125.50
Dec 4, 2024 127.69 2.30 1.83% 125.39 127.80 124.95
Dec 3, 2024 125.38 0.07 0.06% 125.31 126.64 124.41
Dec 2, 2024 125.50 -0.10 -0.08% 125.60 127.73 124.68
Nov 29, 2024 126.50 0.47 0.37% 126.03 126.95 124.97
Nov 27, 2024 126.40 -0.50 -0.39% 126.90 127.46 125.18
Nov 26, 2024 127.83 0.93 0.73% 126.90 128.06 123.31
Nov 25, 2024 126.89 1.14 0.91% 125.75 127.70 124.61
Nov 22, 2024 125.25 0.30 0.24% 124.95 126.85 123.96

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Neurocrine Company profile

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Neurocrine Biosciences, Inc. revenues increased 8% to $1.13B. Net income decreased 78% to $89.6M. Revenues reflect Net product sales increase of 10% to $1.09B. Net income was offset by General and administrative -others increase of 36% to $497.5M (expense), Research and development - others increase of 16% to $279.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 110M auth. 55,200,641 issd. Insiders own 1.73%. IPO: 5/96, 4,394,286 shares (1,214,286 by the Company) @ $10.50 by Robertson, Stephens & Co. LLC. PO: 12/00, 3M shares @ $30 by Robertson Stephens. PO 12/01, 3.5M shares @ $46.75 by Deutsche Banc Alex. Brown. FY'00 Q's are restated.

Industry: Bio Therapeutic Drugs

12780 El Camino Real
SAN DIEGO
CALIFORNIA 92130-2042
US

People also watch

XRP/USD

2.22 Price
-0.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01107

BTC/USD

95,385.90 Price
-1.350% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

TSLA

422.33 Price
-3.790% 1D Chg, %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 0.19

ETH/USD

3,291.68 Price
-0.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading